We postulated that LATS1/2 loss reduces MHC-I expression and impairs MHC-I-mediated antigen presentation in tumor cells, leading to a decrease in CD8+ T cells infiltration in allograft tumors. The gene discussed is CD8A; the disease is neoplasm.